Daniel Dstteffano, MD
General Practice · Manati, PRNPI 1740531011
Payments from drug & device makers
Across 254 payments — averaging $17.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$524
- GSK$385
- Sunovion Pharmaceuticals Inc.$346
- Novartis$317
- Lilly USA, LLC$300
- Astellas Pharma US Inc$281
- plus $2K from 31 others
What the payments were for
- Speaking & faculty fees$220%
- Food & beverage$4,24295%
- Education$1984%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 33 | $524 |
| GSK | 21 | $385 |
| Sunovion Pharmaceuticals Inc. | 20 | $346 |
| Novartis | 18 | $317 |
| Lilly USA, LLC | 20 | $300 |
| Astellas Pharma US Inc | 7 | $281 |
| AstraZeneca | 17 | $275 |
| Johnson & Johnson(2 entities) | 15 | $259 |
| Amgen | 14 | $228 |
| Otsuka America Pharmaceutical, Inc. | 5 | $207 |
| Boehringer Ingelheim | 15 | $202 |
| Novo Nordisk | 13 | $197 |
| Teva Pharmaceuticals USA, Inc. | 8 | $150 |
| Nestle Healthcare Nutrition Inc. | 6 | $94 |
| Pfizer | 6 | $91 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $73 |
| Exact Sciences | 4 | $67 |
| Bayer | 3 | $59 |
| Sanofi-aventis U.S. LLC | 3 | $56 |
| Vivus LLC | 3 | $49 |
| Sun Pharmaceutical Industries Inc. | 2 | $35 |
| Amarin Pharma, Inc. | 2 | $26 |
| Abbott | 1 | $23 |
| Shield Therapeutics Inc | 1 | $22 |
| Acorda Therapeutics, Inc | 1 | $22 |
| Daiichi Sankyo Inc. | 1 | $21 |
| Neurocrine Biosciences, Inc. | 1 | $18 |
| Alkermes, Inc. | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Biohaven Pharmaceuticals, Inc. | 1 | $15 |
| Merck | 1 | $14 |
| Biogen | 1 | $14 |
| Radius Health, Inc. | 1 | $14 |
| Galderma Laboratories, L.p. | 1 | $14 |
| Vanda Pharmaceuticals Inc. | 1 | $12 |
| Evoke Pharma, Inc. | 1 | $11 |
| Arbor Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REXULTI$122
How this compares
$4,462 in reported general payments places this provider in the 95th percentile of 3,586 general practice providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 103 | $164,776 |
| OzempicSemaglutide | 119 | $164,085 |
| FarxigaDapagliflozin Propanediol | 137 | $145,435 |
| EliquisApixaban | 104 | $110,264 |
| Cosentyx Sensoready PenSecukinumab | 11 | $94,300 |
| JardianceEmpagliflozin | 65 | $75,089 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 40 | $58,366 |
| Spiriva RespimatTiotropium Bromide | 52 | $48,110 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 50 | $45,617 |
| EntrestoSacubitril/Valsartan | 30 | $36,141 |
| TradjentaLinagliptin | 41 | $34,517 |
| JanuviaSitagliptin Phosphate | 27 | $32,440 |
| XareltoRivaroxaban | 30 | $28,087 |
| RexultiBrexpiprazole | 14 | $27,921 |
| Xtampza ErOxycodone Myristate | 31 | $24,906 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Spiriva Respimat, Synjardy Xr, Tradjenta, Stiolto Respimat | $202 | $228,046251 claims |
| Lilly USA, LLCTrulicity | $300 | $164,776103 claims |
| Novo NordiskOzempic | $197 | $164,085119 claims |
| AstraZenecaFarxiga, Symbicort | $275 | $158,951172 claims |
| PfizerEliquis | $91 | $110,264104 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $385 | $81,09370 claims |
| NovartisEntresto | $317 | $36,14130 claims |
| MerckJanuvia | $14 | $32,44027 claims |
| Johnson & JohnsonXarelto | $259 | $28,08730 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $207 | $27,92114 claims |
| Astellas Pharma US IncMyrbetriq | $281 | $19,17930 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $346 | $13,38811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,586 general practice providers in Puerto Rico.
Other general practice in Manati
- Gregorio Cortes-MaisonetSan Juan$12.8M
- Barbara Orozco PerezCanovanas$5.1M
- Jesus Rodriguez RodriguezPonce$4.9M
- Luis PaganDorado$3.3M
- Cindy MartinezHormigueros$3.2M
- Gustavo AlbizuMorovis$3.1M
- Elham GhorbaniDorado$1.2M
- Victor MorenoMaunabo$903K
- Grisselle Ortiz RiveraMorovis$715K
- Elba PerezTrujillo Alto$651K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.